Senseonics Sells Diabetes Business

TL;DR

Senseonics is selling its diabetes biz to focus on other tech. Deal closes Q4 2025.

AI Summary

Senseonics Holdings, Inc. announced on October 6, 2025, that it has entered into a definitive agreement to sell its diabetes business to an undisclosed buyer. The transaction is expected to close in the fourth quarter of 2025. This divestiture is part of Senseonics' strategy to focus on its implantable diagnostic technologies.

Why It Matters

This sale signifies a strategic shift for Senseonics, potentially impacting its future product development and financial trajectory as it pivots to other diagnostic areas.

Risk Assessment

Risk Level: medium — The sale of a business unit introduces uncertainty regarding future revenue streams and the success of the company's new strategic focus.

Key Players & Entities

• Senseonics Holdings, Inc. (company) — Registrant
• October 6, 2025 (date) — Date of earliest event reported
• fourth quarter of 2025 (date) — Expected closing of the transaction

FAQ

Key Financial Figures

• $8.1 million — nary unaudited revenue of approximately $8.1 million in the third quarter of 2025, an increa

Filing Documents

• tm2528234d1_8k.htm (8-K) — 27KB
• 0001104659-25-097581.txt ( ) — 187KB
• sens-20251006.xsd (EX-101.SCH) — 3KB
• sens-20251006_lab.xml (EX-101.LAB) — 33KB
• sens-20251006_pre.xml (EX-101.PRE) — 22KB
• tm2528234d1_8k_htm.xml (XML) — 3KB

Forward Looking Statements

Forward Looking Statements Any statements in this report about future expectations, plans and prospects for the Company, including the anticipated revenue results for the third quarter of 2025 constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the financial close process in connection with the finalization of the Company's third quarter 2025 financial statements, as well as the review of such financial statements by the Company's independent registered public accounting firm and such other factors as are set forth in the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and subsequent reports filed with the Securities and Exchange Commission under the heading "Risk Factors." The forward-looking statements included in this report represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law. These forward-looking Preliminary Unaudited Financial Information The preliminary financial information presented in this report are estimates based on information available to management as of the date of this report, have not been reviewed or audited by the Company's independent registered public accounting firm and are subject to change. There can be no assurance that the Company's actual reviewed financial

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 7, 2025 SENSEONICS HOLDINGS, INC. By: /s/ Rick Sullivan Name: Rick Sullivan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR